A second cohort joins Tech4Eva accelerator

Please login or
register
31.03.2022
symbolic picture women

Following the successful launch last year, the Tech4Eva accelerator program supporting startups specialising in female health is taking place for the second time. The 9-month program will help 28 startups advance to the next level – six participants are based in Switzerland.

An initiative based on collaboration between Groupe Mutuel and the EPFL Innovation Park, Tech4Eva aims to promote the best solutions in FemTech and enable them to test their market, secure finance, co-create with their peers. The program attracted applications from 124 projects from 30 countries for its second edition. Female-led projects account for 80% of the submissions.

The jury has selected 28 projects to join the program. b-rayz and Pregnolia, which are among six projects led by Swiss startups, are in the growth stage.

b-rayZ AG – developed a revolutionary AI solution for early breast cancer diagnosis. Its CE-Marked b-box is a novel artificial Intelligence platform that supports technicians in their daily work by assessing breast density and mammographic image quality.

Pregnolia AG –created a diagnostic tool measuring the stiffness of the cervical tissue of a pregnant woman and its changes during pregnancy to avoid the probability of premature delivery.

Deliver Health– offers consultancy services related to Sexual and Reproductive Health and Rights (SRHR), including evaluation of programs, qualitative implementation research and strategic advice for clients globally.

FimmCyte fimmcyte.com – developing a novel immune system-based treatment for women with late-stage endometriosis. Its OoSite platform ensures its endometriosis treatments are active where it matters and inactive where it is not needed to minimise side effects. Early studies have already delivered positive results.

Navina+ – wants to help women navigate their menopause.

OncoGenomX – developed PredictionStar, the first point-of-care (POC) precision oncology software for Breast Cancer diagnostics. It analyses tumour-specific genomic, biological, pathological, digital imaging and patient-specific clinical information. Together with drug and tumour matching, it supports tailor-made therapy decisions at any stage of the disease trajectory, according to company information.

Experienced mentors to support the startups
In 2022, 29 mentors from leading companies, such as CSEM, Essity, Ferring, Gedeon Richter Preglem, Merck, Philips, Procter & Gamble and UCB, will participate in the initiative. The experts from these companies will support the startups during their development phase. The programme has also secured a major partner in CSEM, which will provide technical support for the startups selected. CSEM plays a vital role in the innovation value chain, leveraging public-private partnerships and closing the gap between basic research and industry.

(Press release/RAN)

0Comments

Company profiles on startup.ch

b-rayZ AG

FimmCyte AG

Pregnolia AG

rss